The Old and the New: Prospects for Non-Integrating Lentiviral Vector Technology
Open accessThe DOI matches its Crossref record; 112 of the 113 references it cites were found in a registry or an index.
Abstract
Lentiviral vectors have been developed and used in multiple gene and cell therapy applications. One of their main advantages over other vectors is the ability to integrate the genetic material into the genome of the host. However, this can also be a disadvantage as it may lead to insertional mutagenesis. To address this, non-integrating lentiviral vectors (NILVs) were developed. To generate NILVs, it is possible to introduce mutations in the viral enzyme integrase and/or mutations on the viral DNA recognised by integrase (the attachment sites). NILVs are able to stably express transgenes from episomal DNA in non-dividing cells or transiently if the target cells divide. It has been shown that these vectors are able to transduce multiple cell types and tissues. These characteristics make NILVs ideal vectors to use in vaccination and immunotherapies, among other applications. They also open future prospects for NILVs as tools for the delivery of CRISPR/Cas9 components, a recent revolutionary technology now widely used for gene editing and repair.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This also prevents the provirus formation while the vector DNA remains one of the primary episome types [10].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“NILVs were optimised and modified to increase the transgene expression and to improvise the safety profile [10].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“NILVs can stably express transgenes from the episomal DNA in non-dividing cells or transiently if the target cells divide both in vitro and in vivo.”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903 · cited 2×
“Lentiviral vectors have been derived from human immunodeficiency virus-1 (HIV-1) and developed by segregating the necessary genetic information to form an infectious particle in different plasmids, while removing the capability for replication [1].”
BackgroundMethodLMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341 · cited 1×
“In the last generation of these vectors, the regulatory protein Rev was removed from the packaging plasmid and coded from a fourth, distinct plasmid [3].”
BackgroundGene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 2×
“In fact, there were several adverse events detected in clinical trials, later described, due to insertional mutagenesis [11,12].”
BackgroundMultiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977 · cited 1×
“Earlier vector generations used three plasmids for vector production: the packaging plasmid that codes for all necessary viral proteins for the particle formation and delivery of the transgene into target cells, the envelope plasmid coding for a glycoprotein that allows for the recognition of target cells, and the tra…”
MethodInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815 · cited 1×
“full-length transfer vector mRNA for incorporation into vector particles and do not rely on the viral protein Tat for transcription in the producer cells [7].”
BackgroundBurns, J. C., Friedmann, T., Driever, W., Burrascano, M., & Yee, J. K. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8033 · Cited by 1,399 · cited 1×
“This envelope protein allows for the recognition of many target cells and also stabilises the vector particle [4], although other viral proteins have been used.”
BackgroundHowe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35798 · Cited by 1,286
Malim, M. H., Hauber, J., Le, S.-Y., Maizel, J. V., & Cullen, B. R. (1989) · Nature · doi:10.1038/338254a0 · Cited by 1,280 · cited 11×
“Importantly, it is plausible to speculate that there may be designs to allow for an all-in-one design to provide the DNA template sequence from the same vector that also expresses the Cas9 protein and guide RNA necessary to enhance this cellular process.”
BackgroundInfluential
Cited by
Novel approaches for vaccine development
Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021) · Cell · doi:10.1016/j.cell.2021.02.030 · Cited by 347
“…(Ads) (Barouch and Picker, 2014; Ertl, 2016), cytomegaloviruses (Barouch and Picker, 2014), adeno‐associated viruses (AAV) (Andari and Grimm, 2020), poxviruses (Conrad and Liu, 2019), herpesviruses (Artusi et al., 2018), and retroviruses (Chen et al., 2018b; Luis, 2020; Stephenson et al., 2016).”
Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges
Mengstie, M. A. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.895713 · Cited by 168
“Hence, the transient expression nature of NILVs in dividing cells, combined with their low immunogenicity makes them the most promising vector candidates to be used in clinical applications (Luis, 2020).”
BackgroundChitosan-Based Nanomaterial as Immune Adjuvant and Delivery Carrier for Vaccines
Gong, X., Gao, Y., Shu, J., Zhang, C., & Zhao, K. (2022) · Vaccines · doi:10.3390/vaccines10111906 · Cited by 155
Approved and marketed nanoparticles for disease targeting and applications in COVID-19
Abdellatif, A. A. H., & Alsowinea, A. F. (2021) · Nanotechnology Reviews · doi:10.1515/ntrev-2021-0115 · Cited by 115
Bouazzaoui, A., Abdellatif, A. A. H., Al-Allaf, F. A., Bogari, N. M., Al-Dehlawi, S., & Qari, S. H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020140 · Cited by 98
“The development of non-integrating lentiviral vector (NILVs) [58], which have the capacity to express transgenes transiently in dividing cells or episomes in non-dividing cells and can also be introduced into different cell types, has been a further interesting advancement in the use of lentiviral vectors.”
BackgroundVirus-Like Particle Mediated CRISPR/Cas9 Delivery for Efficient and Safe Genome Editing
Lyu, P., Wang, L., & Lu, B. (2020) · Life · doi:10.3390/life10120366 · Cited by 88
Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through
Gurumoorthy, N., Nordin, F., Tye, G. J., Wan Kamarul Zaman, W. S., & Ng, M. H. (2022) · Biomedicines · doi:10.3390/biomedicines10010107 · Cited by 69
“NILVs were optimised and modified to increase the transgene expression and to improvise the safety profile [10].”
MethodTargeting and delivery of microRNA-targeting antisense oligonucleotides in cardiovascular diseases
Saenz‐Pipaon, G., & Dichek, D. A. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.12.003 · Cited by 56
Therapy Development by Genome Editing of Hematopoietic Stem Cells
Koniali, L., Lederer, C. W., & Kleanthous, M. (2021) · Cells · doi:10.3390/cells10061492 · Cited by 54
“Conversely, disease correction by application of conceptually safer, non-integrating vectors remains transient and inefficient by comparison, despite considerable research efforts [26,27].”
BackgroundAdvances in the Development and the Applications of Nonviral, Episomal Vectors for Gene Therapy
Mulia, G. E., Picanço‐Castro, V., Stavrou, E. F., Athanassiadou, A., & Figueiredo, M. L. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.310 · Cited by 42
“An inbetween case is that of nonintegrating viruses, which have been derived from integrating viruses engineered to be integrase deficient, for example, nonintegrating lentiviruses.(3,4) Nonintegrating viral vectors present an interesting development to the field and can provide stable transgene expression in quiescen…”
BackgroundStrategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges
Yoder, K. E., Rabe, A. J., Fishel, R. A., & Larue, R. C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.662331 · Cited by 41
“Nonintegrating lentiviral vectors with enzymatic mutations of integrase are in development but have not yet entered clinical use (reviewed in (Luis, 2020)).”
BackgroundHarnessing the evolving CRISPR/Cas9 for precision oncology
Li, T., Li, S., Kang, Y., Zhou, J., & Yi, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05570-4 · Cited by 39
“The integration of lentiviral vectors into the human chromosome may pose uncontrolled risks, despite ongoing efforts to avert their chromosomal integration [267].”
BackgroundManagement of adrenoleukodystrophy: From pre-clinical studies to the development of new therapies
Ma, C. Y., Li, C., Zhou, X., Zhang, Z., Jiang, H., Liu, H., Chen, H. J., Tse, H., Liao, C., & Lian, Q. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112214 · Cited by 33
Exploring Advanced CRISPR Delivery Technologies for Therapeutic Genome Editing
Rostami, N., Gomari, M. M., Choupani, E., Abkhiz, S., Fadaie, M., Eslami, S. S., Mahmoudi, Z., Zhang, Y., Puri, M., Monfared, F. N., et al. (2024) · Small Science · doi:10.1002/smsc.202400192 · Cited by 31
Clinical and Translational Landscape of Viral Gene Therapies
Yudaeva, A., Kostyusheva, A. P., Kachanov, A., Brezgin, S. A., Ponomareva, N., Parodi, A., Pokrovsky, V. S., Lukashev, A. N., Chulanov, V., & Kostyushev, D. S. (2024) · Cells · doi:10.3390/cells13221916 · Cited by 31
Rintz, E., Higuchi, T., Kobayashi, H., Galileo, D. S., Węgrzyn, G., & Tomatsu, S. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.11.007 · Cited by 33
“These LVs form nucleosomes that lead to chromatic silencing associated with histone modification in this chromatin structure.(90) With a higher capacity for transgene and elimination of potential mutagenesis associated with integration, nonintegrated LVs have a potential advantage over AAV vectors.”
BackgroundEmbryo and fetal gene editing: Technical challenges and progress toward clinical applications
Mattar, C. N. Z., Chew, W. L., & Lai, P. S. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101229 · Cited by 26
“…supra-physiological protein levels resulting from loss of physiological controls at ectopic production sites may disrupt cellular homeostasis, 34 – 36 but promising studies have shown that a wide range of ectopic expression levels of clotting factors IX and VIII can correct hemophilia, are…”
BackgroundRNA Structure: Past, Future, and Gene Therapy Applications
Haseltine, W. A., Hazel, K., & Patarca, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010110 · Cited by 28
Integrase-Defective Lentiviral Vector Is an Efficient Vaccine Platform for Cancer Immunotherapy
Morante, V., Borghi, M., Farina, I., Michelini, Z., Grasso, F., Gallinaro, A., Cecchetti, S., Virgilio, A. D., Canitano, A., Pirillo, M. F., et al. (2021) · Viruses · doi:10.3390/v13020355 · Cited by 23
“IDLVs are currently under evaluation for gene therapy and vaccines in preclinical and clinical studies [24,25].”
BackgroundGene modification therapies for hereditary diseases in the fetus
Mattar, C. N. Z., Chan, J. K. Y., & Choolani, M. A. (2023) · Prenatal Diagnosis · doi:10.1002/pd.6347 · Cited by 28
Vaccines as Potential Frontliners Against Antimicrobial Resistance (AMR): A Focused Review
Patil, S., Singh, I. P., Verma, I. K., Kumar, A., Sharma, J., Ratn, A., Dhakad, M. S., & Sharma, D. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s544665 · Cited by 26
Integrase deficient lentiviral vector: prospects for safe clinical applications
Yew, C.-H. T., Gurumoorthy, N., Nordin, F., Tye, G. J., Zaman, W. S. W. K., Tan, J. J., & Ng, M. H. (2022) · PeerJ · doi:10.7717/peerj.13704 · Cited by 21
“PeerJ 10:e13704 http://doi.org/10.7717/peerj.13704 (Apolonia, 2020).”
InfluentialEmerging trends in virus and virus-like particle gene therapy delivery to the brain
Mandalawatta, H. P. P., Rajendra, K. C., Fairfax, K. A., & Hewitt, A. W. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102280 · Cited by 22
“114 Although the modi fi ed virus serotypes are useful to target distinct cell populations, safety drawbacks have prevented certain viral vector-based approaches from being utilized for clinical applications, and, therefore, the search for alternative delivery strategies has been intensi fi ed.”
BackgroundCRISPR medicine for blood disorders: Progress and challenges in delivery
Gol, T. M., Ureña-Bailén, G., Hou, Y., Sinn, R., Antony, J. S., Handgretinger, R., & Mezger, M. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.1037290 · Cited by 19
“These modified viruses will harbor non-replicating episomes, which have certain limitations such as loss over time in rapid-dividing cells, lower transgene expression in comparison to traditional lentiviruses and risk of residual integration (Luis, 2020; Gurumoorthy et al., 2022).”
BackgroundGene Therapy for Neuronopathic Mucopolysaccharidoses: State of the Art
de Castro, M. J., del Toro, M., Giugliani, R., & Couce, M. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179200 · Cited by 17
Yari, F., Ashoub, M. H., Amirizadeh, N., Nikougoftar, M., Valandani, H. M., & Khalilabadi, R. M. (2023) · Biochemical Genetics · doi:10.1007/s10528-023-10565-9 · Cited by 14
Advances and challenges in gene therapy strategies for pediatric cancer: a comprehensive update
Moaveni, A. K., Amiri, M., Shademan, B., Farhadi, A., Behroozi, J., & Nourazarian, A. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1382190 · Cited by 14
Bona, R., Michelini, Z., Mazzei, C., Gallinaro, A., Canitano, A., Borghi, M., Vescio, M. F., Virgilio, A. D., Pirillo, M. F., Klotman, M. E., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.09.011 · Cited by 12
In Utero Gene Therapy and its Application in Genetic Hearing Loss
Kong, C., Yin, G., Wang, X., & Sun, Y. (2024) · Advanced Biology · doi:10.1002/adbi.202400193 · Cited by 12
Viral-mediated gene therapy in pediatric neurological disorders
Peng, J., Zou, W., Wang, X., Zhang, Z., Huo, R., & Yang, L. (2023) · World Journal of Pediatrics · doi:10.1007/s12519-022-00669-4 · Cited by 11
CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers
Kostyushev, D. S., Kostyusheva, A. P., Ponomareva, N. I., Brezgin, S. A., & Chulanov, V. (2021) · Nucleic Acid Therapeutics · doi:10.1089/nat.2021.0075 · Cited by 9
“In contrast, nonintegrating lentiviral vectors lack insertional mutagenesis and exhibit low immunogenicity, large packaging capacity, and transient expression of transgenes, making them perspective vehicles for delivering CRISPR/Cas9 in vivo [67].”
Esmaeilzadeh, A., Hadiloo, K., Yaghoubi, S., Makoui, M. H., & Mostanadi, P. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01056-7 · Cited by 8
“To minimize insertional mutagenesis, non-integrating LVs and mRNA-based CAR expression avoid permanent genome modification, reducing the risk of oncogenesis [111 , 114 ].”
Li, J., Tang, C., Liang, G., Tian, H., Lai, G., Wu, Y., Liu, S., Zhang, W., Liu, S., & Shao, H. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.115 · Cited by 9
“112 However, LV-mediated CRISPR-Cas9 gene editing is a safety hazard because the LV genome can randomly integrate into the genomes of somatic cells, limiting its clinical applications.”
Towards a Cure for Diamond–Blackfan Anemia: Views on Gene Therapy
Vale, M., Procházka, J., & Sedláček, R. (2024) · Cells · doi:10.3390/cells13110920 · Cited by 9
Research Progress of Microneedles in Vaccine Delivery
Qiao, X., Liu, D., Pan, W., He, M., & Meng, F. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673336874241129081141 · Cited by 6
How CRISPR Is Revolutionizing the Generation of New Models for Cancer Research
Rivera, F. J. S., & Dow, L. E. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041384 · Cited by 6
Vesin, B., Fert, I., Noirat, A., Authié, P., Ciret, S., Blanc, C., Vitrenko, Y. A., Charneau, P., Majlessi, L., & Anna, F. (2025) · npj Vaccines · doi:10.1038/s41541-025-01199-6 · Cited by 5
A robust method for protein depletion based on gene editing
Yang, Y., Wu, W., Liu, T., Dong, L., & Lei, H. (2021) · Methods · doi:10.1016/j.ymeth.2021.03.001 · Cited by 3
Papillomavirus-like particles as vectors for ex vivo gene therapy of the skin
Diversi, F., Dabin, J., Mazza, E., Rinaldin, M., Reis, F. D. C., Hackett, J. A., & Heppenstall, P. A. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102501 · Cited by 2
“20 In contrast, our experiments demonstrated that PVLPs achieved transduction ef fi ciencies in primary keratinocytes that were superior to those of integrating lentiviruses.”
Windisch, R., Soliman, S. S., Hoffmann, A., Chen-Wichmann, L., Danese, A., Vosberg, S., Bravo, J., Lutz, S., Kellner, C., Fischer, A. H., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2312499121 · Cited by 2
Ciganek, I., Delehedde, C., Galy, A. H. M., Cogné, M., Rameix, N., Bordeianu, C., & Pichon, C. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103334 · Cited by 3
“They enable transient-to-sustained episomal expression, thus increasing the safety profile and offering new avenues for the employment of this approach for CRISPR delivery [106,107].”
Fehse, B., Schickl, H., Bartfeld, S., & Zenke, M. (2023) · Springer eBooks · doi:10.1007/978-3-662-67908-1 · Cited by 3
Application Advances of Lentiviral Vectors: From Gene Therapy to Vaccine Development
Fang, E., He, G., Chang, Y., He, Q., Chen, P., & Hu, K. (2025) · Molecular Biotechnology · doi:10.1007/s12033-025-01472-y · Cited by 8
Advances in approaches to study cell-type specific cortical circuits throughout development
Hanson, M. A., & Wester, J. C. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.1031389 · Cited by 2
“However, non-integrating vectors are in development (Luis, 2020), thus lentivirus may remain the best in vivo delivery strategy for CRISPRoff and CRISPRon.”
BackgroundOncolytic Viruses and Viral Gene Therapy Vectors: Principles of Safety
Spiesschaert, B., & Gautam, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-28489-2_18 · Cited by 3
Λαζανά, Ι., Simantirakis, E., Kourous, E., Daniil, M., Ioannou, D., & Vassilopoulos, G. (2025) · Immunology · doi:10.1111/imm.70018 · Cited by 1
Ma, M.-R., Song, X., Wang, X.-K., Liu, Y., Cai, X., Zheng, R.-R., Liu, M., Ma, L., Wang, F., & Ma, L. (2025) · Gene · doi:10.1016/j.gene.2025.149866 · Cited by 2
Episomal Vectors: Principle, Utility, and Application
Sato, M., Inada, E., Watanabe, S., Saitoh, I., Kubota, N., Iwase, Y., Morohoshi, K., & Nakamura, S. (2025) · OBM Genetics · doi:10.21926/obm.genet.2504317 · Cited by 2
Jalise, S. Z., Milan, P. B., Kialashaki, E., Ghane, M., Habibi, S., & Mehrabi, A. (2026) · Macromolecular Bioscience · doi:10.1002/mabi.202500453 · Cited by 4
Nucleic acid-based therapeutic strategies for modulator-refractory cystic fibrosis-causing variants
Leahy, M. D., Zollo, I., Clarke, L. A., & Farinha, C. M. (2026) · Human Molecular Genetics · doi:10.1093/hmg/ddag058 · Cited by 1
Gentherapie aus der Sicht eines forschenden Arzneimittelunternehmens
Cohnen, A., Hoffmeister, L., & Schulte, A. M. (2023) · Springer eBooks · doi:10.1007/978-3-662-67908-1_16 · Cited by 1
Special Issue “Lentiviral Vectors”
Takeuchi, Y. (2022) · Viruses · doi:10.3390/v14071492 · Cited by 1
“Another type of modification in these lentiviral elements is the engineering to turn the vector into a non-integrating or integration-deficient LV (NILV/IDLV), which was reviewed in [2].”
BackgroundDNA‐ and RNA‐Based Viral Vectors
Kapoor, D. U., Bhatt, B., Sahu, D., Kakkar, R., Gandhi, S. M., & Gautam, R. K. (2025) · Wiley eBooks · doi:10.1002/9781394271566.ch7 · Cited by 2
Clinic viral diagnostics, viral vaccines, and advanced immunology
Upreti, S., & Samant, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15241-2.00007-7
Gabriel, E. M., Necela, B. M., Bahr, D. A., Vivekanandhan, S., Shreeder, B., Bagaria, S. P., & Knutson, K. L. (2024) · Scientific Reports · doi:10.1038/s41598-024-76209-z
Adeniran, A., Handy, S., & Baki, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-62007-2_9
Modern approaches to the construction and use of recombinant viruses
Prokhorova, P. V., Vlasova, N. N., Геннадиевич, Ю. А., & Gulyukin, A. M. (2025) · Problems of Virology · doi:10.36233/0507-4088-323
“However, IDLV is characterized by a significantly lower level of expression compared to integrating lentiviruses [92, 93], as well as a lower risk of insertional mutagenesis [94].”
Wright, J., Alberts, B. M., Quiles, M. L. M., Guarino, A., Chipchase, D., Clarkson, N. G., Mitrophanous, K. A., & Farley, D. C. (2025) · Molecular Therapy Advances · doi:10.1016/j.omta.2025.201654
“Toward “SupA2KO” LVs: Pairing supA-LTRs and MSD-mutated LV genomes In previous work, we have developed MSD-mutated LV genomes to ablate aberrant splicing from the packaging signal into the transgene cassette during LV production, which we refer to as “2KO-LVs.””
InfluentialSurface engineering of cell-derived particles for targeted delivery of genome editors
DeAgazio, C., Singh, A., & Banskota, S. (2026) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2026.102815
Metadata
- Authors
- Apolonia, L.
- Affiliations
- King's College London (GB)
- Corresponding author
- Apolonia, Luis
- ORCID
- Apolonia, Luis
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2020-09-29
- Volume
- 12
- Issue
- 10
- Pages
- 1103
- ISSN
- 1999-4915 (ISSN-L)
- PMC
- PMC7600637
- OpenAlex
- W3089800965
- Semantic Scholar
- 324fbc09f8fa809d5a516e0740b3caede616fe8f
- Cited by
- 58
- References
- 113
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 13 · 2023: 9 · 2022: 7 · 2021: 13 · 2020: 1
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Viruses (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- lentiviral vectors, integrase mutations, insertional mutagenesis, episomal DNA, transgene expression, gene therapy, cell therapy, vaccination, immunotherapy, CRISPR/Cas9 delivery, genome editing
- MeSH terms
- DNA, Viral, Genetic Vectors, Immunotherapy, Plasmids, Genetic Therapy, Gene Expression, Lentivirus, Mutagenesis, Transgenes, Integrases, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.